Cross-talk between TRPC-1, mTOR, PGC-1α and PPARδ in the dystrophic muscle cells treated with tempol

Area of Science:

• Biochemistry
• Cell Biology
• Molecular Biology

Background:

• Calcium (Ca2+) dysregulation and oxidative damage are key factors in Duchenne muscular dystrophy (DMD) progression.
• Primary muscle cells from dystrophic models exhibit these pathological hallmarks.
• Understanding molecular targets is crucial for developing effective DMD therapies.

Purpose of the Study:

• To investigate the effects of Tempol, an antioxidant, on specific molecular pathways in dystrophic muscle cells.
• To assess Tempol's impact on calcium handling, muscle differentiation regulators, antioxidant systems, mitochondrial biogenesis, and inflammation.
• To elucidate the role of the TRPC1 channel in Tempol's therapeutic action.

Main Methods:

• Primary muscle cells (myotubes) from mdx mice (dystrophic model) were treated with Tempol (5 mM) for 24 hours.
• Control groups included untreated mdx myotubes and myotubes from healthy C57BL/10 mice.
• Cell viability, intracellular calcium levels, gene/protein expression, and oxidative stress markers were analyzed.

Main Results:

• Tempol (5 mM) showed no cytotoxic effects on dystrophic muscle cells.
• Tempol treatment significantly reduced intracellular calcium, TRPC1 channel activity, and oxidative stress markers (H2O2, O2•−, 4-HNE).
• Tempol increased the expression of antioxidant enzymes (SOD, CAT, GR) and promoted muscle differentiation (Myogenin, MHC-Slow) and mitochondrial biogenesis (mTOR, PGC-1α, PPARδ).

Conclusions:

• Tempol effectively mitigates intracellular calcium overload and oxidative stress in primary dystrophic muscle cells.
• The study highlights a crosstalk between TRPC1, mTOR, PGC-1α, and PPARδ pathways modulated by Tempol.
• Tempol demonstrates therapeutic potential for Duchenne muscular dystrophy by targeting key pathological mechanisms.